Douglas Melton, one of the leading stem cell researchers in the world, is leaving Harvard University to join Vertex Pharmaceuticals, where he says he will pursue his deeply personal, decades-long quest to create therapies for type 1 diabetes.
Both his adult children have the disease, which affects the regulation of blood sugar and afflicts 1.9 million Americans.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
